Belcesiran ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
231α1−アンチトリプシン欠乏症2

231. α1−アンチトリプシン欠乏症


臨床試験数 : 93 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04764448
(ClinicalTrials.gov)
February 12, 202127/1/2021A Study of Belcesiran in Patients With AATLDA Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseAlpha 1-Antitrypsin DeficiencyDrug: Belcesiran;Other: PlaceboDicerna Pharmaceuticals, Inc.NULLRecruiting18 Years75 YearsAll46Phase 2Australia;Austria;Belgium;Canada;France;Germany;Ireland;Netherlands;New Zealand;Portugal;Spain;Sweden;United Kingdom
2NCT04174118
(ClinicalTrials.gov)
October 24, 20196/11/2019Study of DCR-A1AT in Healthy Adult VolunteersA Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult VolunteersAlpha 1-Antitrypsin DeficiencyDrug: belcesiran;Drug: PlaceboDicerna Pharmaceuticals, Inc.NULLActive, not recruiting18 Years55 YearsAll30Phase 1New Zealand;Sweden